Apps and online platforms available in Switzerland (as of 10/2019):
BioPath is an intuitive web portal that collects and visualizes PD-L1 ("programmed cell death ligand-1") test results as predictive biomarkers for specific immune-oncological treatment concepts. This allows data comparisons of both PD-L1 prevalence and testing methodology between a local test center and the national average. BioPath was created in close collaboration with Swiss pathologists in Switzerland with the aim to increase the quality of biomarkers testing, starting with PD-L1.
Website
EndoCase is an interactive online platform for diabetologists and endocrinologists, which presents interesting patient cases every two months.
To the platform
Glycemizer allows physicians to easily determine individual HbA1c target ranges for patients with type 2 diabetes in less than two minutes. Glycemizer has been developed and validated by Swiss diabetologists and endocrinologists in collaboration with MSD.
Contact: glycemizer@merck.com
Website
The GP Tool is a practical guide to managing patients with type 2 diabetes. It contains a therapy algorithm and provides an overview of the different therapy approaches for the treatment of type 2 diabetes. The GP tool is based on recommendations of the Swiss Diabetes Society (SDG).
Website
iBDialog monthly provides patients with chronic inflammatory bowel diseases and their gastroenterologists with a continuous overview of the course of the therapy. Patients record their disease activity and medication with a simple and short questionnaire. iBDialog monthly was developed by MSD in close cooperation with leading gastroenterologists from IBDnet and the patient organization Crohn Colitis Schweiz.
Website
iBDialog is available on the App Store for iOS devices.
Our mission is simple: We believe that health information is a universal right and that every person is entitled to accurate and accessible medical information. We have a responsibility to protect, preserve and share the best current medical information to enable more informed decisions, enhance relationships between patients and professionals, and improve health care outcomes around the world. That’s why we are making the Merck Manuals and the MSD Manuals available for free in digital form in multiple languages to professionals and patients around the world.
Go to MSD Manual
The MSD PARIS (Patient at Risk Identification System) software developed by MSD supports the identification of diabetic and cardiovascular risk patients in the GP's practice. With MSD PARIS, the risk of the disease can be estimated based on patient data - as a foundation for determining the best possible therapy. In addition, the software is intended to avoid over- and under-treatment, use resources more efficiently and make therapy success more measurable.
Learn more
Contact: paris.ch@merck.com
Successful treatment of a diagnosed disease can begin with simple explanations. In daily physician-patient communication, anatomical drawings can be an important tool to explain a disease. MSD Sketchbook helps! 18 anatomical drawings can be used to quickly and easily explain a patient's state of health.
MSD Sketchbook is available on the App Store for iOS devices.
myPH is a mobile app that PH patients can use to easily document the course of their disease. The physician has access to the recorded data, which helps him to track the course of the patient's disease until the next consultation. myPH was developed by the PH Expert Center at Geneva University Hospital in close cooperation with MSD.
Learn more
With mySCQM, rheumatologists and patients with inflammatory rheumatism have a simple and modern way of documenting disease activity and medication intake between physician check-ups. This information helps to better assess the course of the disease and to make the therapy more effective. The app was jointly operated by MSD in close cooperation with the SCQM Foundation from 2016 to the end of 2018 and has since then been continued by SCQM as 'mySCQM'.
Learn more
Current medical and health policy news at a glance as well as direct access to the content relevant for you.
To the website
CH-NON-00071, 03/2019